Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × pCR Rate × Docetaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 271 Carcinoma, Non-Small-Cell Lung 195 Prostatic Neoplasms 171 Stomach Neoplasms 100 Lung Neoplasms 93 Squamous Cell Carcinoma of Head and Neck 72 Head and Neck Neoplasms 67 Esophageal Neoplasms 56 Neoplasms 47 Neoplasm Metastasis 36 Pancreatic Neoplasms 31 Nasopharyngeal Carcinoma 30 Ovarian Neoplasms 27 Sarcoma 26 Urinary Bladder Neoplasms 25 Triple Negative Breast Neoplasms 20 Adenocarcinoma 19 Carcinoma, Squamous Cell 17 Adenocarcinoma Of Esophagus 17 Esophageal Squamous Cell Carcinoma 16 Carcinoma, Ovarian Epithelial 15 Unspecified Adult Solid Tumor, Protocol Specific 13 Carcinoma, Transitional Cell 13 Breast Neoplasms, Male 13 Adenocarcinoma of Lung 12 Salivary Gland Neoplasms 11 Laryngeal Neoplasms 11 Small Cell Lung Carcinoma 10 Inflammatory Breast Neoplasms 10 Uterine Cervical Neoplasms 9

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡